Endocrine Therapy Predominant Therapeutic Option in HR+/HER2-Negative Advanced Breast Cancer

Endocrine Therapy Predominant Therapeutic Option in HR+/HER2-Negative Advanced Breast Cancer

header-info

According to a retrospective cohort analysis, endocrine therapy in the first-line was found to be the predominant therapeutic option for hormone receptor-positive HER2-negative advanced breast cancer (HR+ HER2- aBC).